Figures & data
Table 1. All study-eligible patients with T2DM: patient characteristics stratified by CVD risk group and payer type.
Figure 1. Patient selection.
Table 2. All study-eligible patients with T2DM: multivariable-adjusted mean PPPM all-cause healthcare costs for patients with T2DM with or without MACE during 1-year follow-up period.
Figure 2. Expected mean PPPM costs of MACE per 100 covered patients with T2DM within CVD risk group by payer type. CVD, cardiovascular disease; MACE, major adverse cardiovascular events (stroke and myocardial infarction); PPPM, per-patient per-month. Expected PPPM costs were calculated from the multivariable-adjusted results as: proportion of patients with MACE within CVD risk group * incremental PPPM cost differences between patients with vs without MACE within CVD risk group * 100. ‘Highest risk’ defined as being aged >40 and having ≥1 baseline claim for atherosclerosis, stroke, MI, unstable angina, coronary re-vascularization, or heart failure; ‘medium risk’ defined as being aged ≥55 (men) or ≥60 (women) and having ≥1 baseline claim for dyslipidemia, hypertension, or tobacco use disorder; ‘lowest risk’ comprised the remaining patients. Medicare is patients with Medicare Supplemental insurance.
